In operation since 2003, NexBio is involved in the development and commercialization of biopharmaceuticals to prevent and treat life-threatening human diseases. It develops Fludase, which is a drug candidate for the prophylaxis and treatment of respiratory infections. The company is also involved in the preclinical development of Viradin, which is an intravenous therapeutic product for sepsis and septic shock, as well as viral hemorrhagic fever caused by various pathogens. NexBio offers TOSAP, which is a proprietary formulation technology capable of creating microspheres and nanospheres for drug delivery.

Wolf's Bar B Q

Fabrus

Genewiz

Afraxis